Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth

2 Visninger
administrator
administrator
08/09/23

this is a brief educational video for dermatology residents and medical students that etiopathogenesis of cutaneous T cell lymphomas.
For any queries mail to: sushruth93@gmail.com

  • Kategori

Vis mere
0 Kommentarer Sorter efter

    Ingen kommentarer fundet

    Facebook kommentarer

    Næste

    Vascular Tumors of Skin (31 cases in 3 hours): Board Review for Pathology Dermatology Dermpath
    02:46:44
    Vascular Tumors of Skin (31 cases in 3 hours): Board Review for Pathology Dermatology Dermpath
    administrator
    5 Visninger
    Actinic Keratosis Treatment and Cancer Potential - Eyelid, Face, and Neck [Dermatology Course 32/60]
    00:01:46
    Actinic Keratosis Treatment and Cancer Potential - Eyelid, Face, and Neck [Dermatology Course 32/60]
    administrator
    4 Visninger
    Sebaceous Carcinoma: Dermpath in 5 Minutes - pathology dermatology dermatopathology skin cancer
    00:03:16
    Sebaceous Carcinoma: Dermpath in 5 Minutes - pathology dermatology dermatopathology skin cancer
    administrator
    5 Visninger
    Basal Cell Carcinoma (BCC) of Eyelid - For Ophthalmology Residents
    00:04:29
    Basal Cell Carcinoma (BCC) of Eyelid - For Ophthalmology Residents
    administrator
    2 Visninger
    Amyloidosis for medical students & dermatology residents I Dr.Ram sushruth
    00:26:14
    Amyloidosis for medical students & dermatology residents I Dr.Ram sushruth
    administrator
    2 Visninger
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    00:03:06
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    administrator
    3 Visninger
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    00:02:51
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    administrator
    2 Visninger
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    00:02:30
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    administrator
    3 Visninger
    The CTCL diagnosis journey
    00:00:20
    The CTCL diagnosis journey
    administrator
    6 Visninger
    Unmet needs for late-stage CTCL
    00:01:10
    Unmet needs for late-stage CTCL
    administrator
    3 Visninger
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    00:01:16
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    administrator
    2 Visninger
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    00:01:35
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    administrator
    4 Visninger
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    00:08:49
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    administrator
    10 Visninger
    Pre-clinical activity of tipifarnib in CTCL
    00:02:12
    Pre-clinical activity of tipifarnib in CTCL
    administrator
    5 Visninger
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    00:04:47
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    administrator
    3 Visninger
    CTCL 06 2017
    02:28:08
    CTCL 06 2017
    administrator
    2 Visninger
    Brentuximab vedotin for CTCL
    00:02:30
    Brentuximab vedotin for CTCL
    administrator
    2 Visninger
    Clonal evolution in patients with CTCL
    00:02:24
    Clonal evolution in patients with CTCL
    administrator
    3 Visninger
    RESMAIN: HDAC inhibitor resminostat for CTCL
    00:01:23
    RESMAIN: HDAC inhibitor resminostat for CTCL
    administrator
    1 Visninger